Updated as of 10/3/14.
The draft clinical criteria for the use of Hep C medication Sofosbuvir (Sovaldi) was presented to the NYS Department Of Health Drug Utilization Review Board (DURB) on Thursday, September 18, 2014.
The meeting summary, including the criteria can be reviewed here. The presentation slides can be reviewed here: Presentation: HCV Direct Acting Antiviral (DAA) Clinical Criteria.
The summary is updated after final determinations are made by the NYS Commissioner of Health.
The audio cast from the meeting is available here.
At this time, the DURB is accepting comments on the criteria. Comments can be sent to: dur@health.ny.gov. The deadline to comment is Monday, October 6th.
Comment!
Last Updated on January 25, 2020 by HepFree NYC
